Connor Clark & Lunn Investment Management Ltd. Purchases 42,383 Shares of Immunic, Inc. (NASDAQ:IMUX)

Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Immunic, Inc. (NASDAQ:IMUX) by 70.8% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 102,257 shares of the company’s stock after purchasing an additional 42,383 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.11% of Immunic worth $169,000 at the end of the most recent quarter.

Separately, Virtu Financial LLC purchased a new position in Immunic in the first quarter worth about $25,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Wall Street Analysts Forecast Growth

IMUX has been the subject of a number of analyst reports. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. B. Riley initiated coverage on shares of Immunic in a report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 target price for the company. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. Leerink Partners reissued an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a research note on Monday, September 9th. Finally, HC Wainwright began coverage on shares of Immunic in a research note on Monday, November 25th. They set a “buy” rating and a $10.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $11.80.

Insider Activity at Immunic

In related news, Director Richard Alan Rudick acquired 87,300 shares of Immunic stock in a transaction dated Tuesday, November 12th. The stock was acquired at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the transaction, the director now owns 87,300 shares of the company’s stock, valued at $100,395. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.00% of the stock is currently owned by company insiders.

Immunic Stock Up 3.3 %

NASDAQ:IMUX opened at $1.24 on Monday. Immunic, Inc. has a 52 week low of $0.97 and a 52 week high of $2.11. The stock’s fifty day moving average is $1.34 and its two-hundred day moving average is $1.34. The company has a market capitalization of $111.70 million, a P/E ratio of -1.01 and a beta of 1.88.

Immunic Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.